Cellectis SA (XPAR:ALCLS)
€ 1.48 -0.02 (-1.33%) Market Cap: 148.14 Mil Enterprise Value: -14.65 Mil PE Ratio: 0 PB Ratio: 1.29 GF Score: 44/100

Cellectis SA Chardan Leadership Call Transcript

May 27, 2020 / 02:00PM GMT
Release Date Price: €17.18 (-6.02%)
Geulah Livshits
Chardan Capital - Analyst

Good morning, and good afternoon to call participants in Europe. Welcome to today's Chardan Leadership Call featuring Cellectis, a company focused on developing off-the-shelf T-cell therapies for cancers.

A special thank you to our guests today, Dr. André Choulika, CEO; Dr. Carrie Brownstein, CMO; and Simon Harnest, VP of Corporate Strategy and Finance, of Cellectis. So Cellectis is participating in this leadership call in conjunction with Chardan Cares, Chardan's fundraising initiative to support the programs and charities that are most important to the companies we work with. Chardan has made a donation to the Multiple Myeloma Research Foundation in Cellectis's name, and we encourage you to support this charity as well as you are able to. For more information, please reach out to our corporate access team.

I'm Geulah Livshits, a biotech analyst at Chardan. And as call participants are aware, our focus at Chardan is on identifying companies that can generate exceptionally high, long-term investment returns by creating and sharing in real

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot